Artax Biopharma Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
9
Artax Biopharma General Information
Description
Developer of small-molecule drugs intended to treat autoimmune and inflammatory diseases. The company's drugs eliminate harmful foreign pathogens while being tolerant of self-tissues and organs that simultaneously allow the body to fight foreign pathogens, enabling doctors to treat both the symptoms and the underlying disease with fewer side effects.
Contact Information
Website
www.artaxbiopharma.comCorporate Office
- 1 Broadway
- 14th Floor
- Cambridge, MA 02142
- United States
Corporate Office
- 1 Broadway
- 14th Floor
- Cambridge, MA 02142
- United States
Artax Biopharma Timeline
Artax Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Accelerator/Incubator | Completed | Clinical Trials - Phase 2 | ||||
| 6. Later Stage VC | 06-Aug-2024 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC (Series B) | 11-May-2022 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series B3) | 29-Apr-2020 | Completed | Pre-Clinical Trials | |||
| 3. Later Stage VC (Series B2) | 08-Aug-2019 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series B) | 22-Sep-2015 | $10M | $12M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC (Series A) | 10-Nov-2014 | $2.01M | $2.01M | Completed | Pre-Clinical Trials |
Artax Biopharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B4 | ||||||||
| Series B3 | ||||||||
| Series B2 | ||||||||
| Series B | 8,750,452 | $0.000100 | $0.09 | $1.14 | $1.14 | 1x | $1.14 | 14.79% |
| Series A | 2,805,396 | $0.000100 | $1.77 | $1.77 | 1x | $1.77 | 4.74% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Artax Biopharma Comparisons
Industry
Financing
Details
Artax Biopharma Competitors (23)
One of Artax Biopharma’s 23 competitors is Abivax, a Formerly PE-Backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Abivax | Formerly PE-Backed | Paris, France | ||||
| Meditope Biosciences | Venture Capital-Backed | Pasadena, CA | ||||
| Equillium | Formerly VC-backed | La Jolla, CA | ||||
| Immunophotonics | Private Equity-Backed | Saint Louis, MO | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD |
Artax Biopharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Artax Biopharma Patents
Artax Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3759086-A1 | Chromene derivatives as inhibitors of tcr-nck interaction | Pending | 27-Feb-2018 | ||
| US-11008310-B2 | Chromene derivatives as inhibitors of tcr-nck interaction | Active | 27-Feb-2018 | ||
| US-10696663-B2 | Chromene derivatives as inhibitors of tcr-nck interaction | Active | 27-Feb-2018 | ||
| US-20200347042-A1 | Chromene derivatives as inhibitors of tcr-nck interaction | Active | 27-Feb-2018 | ||
| US-20190263792-A1 | Chromene derivatives as inhibitors of tcr-nck interaction | Active | 27-Feb-2018 | C07D311/58 |
Artax Biopharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Artax Biopharma Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Dosbio50 | Venture Capital | Minority | ||
| Eli Lilly | Corporation | Minority | ||
| Sound Bioventures | Venture Capital | Minority | ||
| Columbus Venture Partners | Venture Capital | Minority |
Artax Biopharma FAQs
-
When was Artax Biopharma founded?
Artax Biopharma was founded in 2013.
-
Where is Artax Biopharma headquartered?
Artax Biopharma is headquartered in Cambridge, MA.
-
What is the size of Artax Biopharma?
Artax Biopharma has 11 total employees.
-
What industry is Artax Biopharma in?
Artax Biopharma’s primary industry is Drug Discovery.
-
Is Artax Biopharma a private or public company?
Artax Biopharma is a Private company.
-
What is Artax Biopharma’s current revenue?
The current revenue for Artax Biopharma is .
-
How much funding has Artax Biopharma raised over time?
Artax Biopharma has raised $48.5M.
-
Who are Artax Biopharma’s investors?
, Dosbio50, Eli Lilly, Sound Bioventures, and Columbus Venture Partners are 5 of 9 investors who have invested in Artax Biopharma.
-
Who are Artax Biopharma’s competitors?
Abivax, Meditope Biosciences, Equillium, Immunophotonics, and NexImmune are some of the 23 competitors of Artax Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
